Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904895 | 0.81 | CHRNB2 (0.49) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL16154951 | 0.78 | CHRNB2 (0.46) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL16050791 | 0.76 | CCNT1 (0.81) | CCNT1CDK9 | |
| SCHEMBL16050790 | 0.76 | CCNT1 (0.81) | CCNT1CDK9 | |
| SCHEMBL7805901 | 0.74 | CHRNB2 (0.54) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL12093045 | 0.74 | CHRNB2 (0.67) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL2881954 | 0.74 | CHRNB2 (0.67) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL6780710 | 0.72 | CCNT1 (0.42) | CCNT1CDK9CHRNB2CHRNA4 | |
| SCHEMBL6780715 | 0.72 | CCNT1 (0.42) | CCNT1CDK9CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL18689619 | 0.72 | CHRNB2 (0.65) | CCNT1CDK9CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880007-B2 | such as 1-bicyclo[2.2.1]hept-2-yl-4-(4-methoxy-2-methyl-phenyl)-piperidine, used for the treatment of chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880007-B2 | such as 1-bicyclo[2.2.1]hept-2-yl-4-(4-methoxy-2-methyl-phenyl)-piperidine, used for the treatment of chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880007-B2 | such as 1-bicyclo[2.2.1]hept-2-yl-4-(4-methoxy-2-methyl-phenyl)-piperidine, used for the treatment of chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1817032-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060287303-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-12-21 | — | — | US | disclosed |
| WO-2006058294-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287303-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CCNT1 4441/4885CDK9 3429/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.